SFO
AGIO icon

Standard Family Office’s Agios Pharmaceuticals AGIO Stock Holding History

Standard Family Office’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-49
Closed -$2K – 78
2021
Q4 		$2K Buy
+49
New +$1.97K 0.02% 183

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Standard Family Office's AGIO Position: Q1 2022 in Review

Standard Family Office sold out of Agios Pharmaceuticals (AGIO) in Q1 2022, closing a stake of 49 shares — an estimated $2K sold.

Standard Family Office first reported a position in AGIO in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q1 2022.

  • Standard Family Office reported no remaining Agios Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Standard Family Office sold 49 Agios Pharmaceuticals shares in Q1 2022, an estimated $2K.
  • Standard Family Office first reported a position in Agios Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Standard Family Office's Agios Pharmaceuticals position peaked at $2K in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2022.

Based on Standard Family Office's 13F filing for Q1 2022, filed 16 May 2022.